- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06006117
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.
The patients will be Randomized as follows:
Arm A - Experimental arm:
• Mosunetuzumab-Lenalidomide
Arm B - Comparator arms ( Investigator Choices):
- Rituximab-Lenalidomide
- Rituximab-Bendamustine
- Rituximab-CHOP
Study Overview
Status
Conditions
Detailed Description
This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.
Patients are stratified according to MZL subtypes and time to progression of disease after first-line within 2 years (POD24) < 2 years or > 2 years.
Mosunetuzumab will be administered sub-cutaneously (SC) (21 days first cycle, then 28 days next cycles) and Lenalidomide will be given PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6. For each patient, investigator choice had to be decided before randomization between Rituximab-Lenalidomide and Rituximab-chemotherapy (R-Bendamustine or R-CHOP).
The primary efficacy endpoint for comparison is the Progression-free survival (PFS) as determined by investigator (Lugano criteria 2014). Secondary objectives include CR24 as determined by investigator (at 24 months) according to Lugano criteria 2014 and by central review based on PET result, Overall response rate (ORR) and CR other than CR24 as determined by investigator, or by central review based on PET result according to Lugano Criteria 2014. 260 patients are planned to be enrolled in France, Belgium, Germany, Italy and Portugal
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Karima BRAHAMI
- Phone Number: 0634533784
- Email: karima.brahami-aissou@lysarc.org
Study Locations
-
-
-
Amiens, France
- Recruiting
- CHU d'Amiens
-
Contact:
- Caroline DELETTE, MD
-
Avignon, France
- Recruiting
- CH d'Avignon - Hopital Henri Duffaut
-
Contact:
- Hacène ZERAZHI, MD
-
Bayonne, France
- Recruiting
- CH de la Côte Basque - Hôpital de Bayonne
-
Contact:
- Sophie BERNARD, MD
-
Besançon, France
- Recruiting
- CHRU Besançon - Hôpital Minjoz
-
Contact:
- Adrien Chauchet, MD
-
Bordeaux, France
- Recruiting
- Institut Bergonie
-
Contact:
- Fontanet BIJOU, Pr
-
Clermont Ferrand, France
- Recruiting
- CHU Estaing
-
Contact:
- Olivier TOURNILHAC, MD
-
Créteil, France
- Recruiting
- CHU Henri Mondor
-
Contact:
- Corinne Haioun
-
Dijon, France
- Recruiting
- CHU de Dijon
-
Contact:
- Olivier CASASNOVAS, MD
-
La Tronche, France
- Recruiting
- CHU de Grenoble - Hôpital Albert Michallon
-
Contact:
- Sylvain Carras, MD
-
Lille, France
- Recruiting
- CHRU de LILLE - Claude Huriez
-
Contact:
- Franck MORSHHAUSER, Pr
-
Marseille, France
- Recruiting
- Institut Paoli Calmette
-
Contact:
- Aude Collignon, MD
-
Montpellier, France
- Recruiting
- CH Saint-Eloi
-
Principal Investigator:
- Guillaume Cartron, MD
-
Contact:
- Guillaume CARTRON, MD
-
Nancy, France
- Recruiting
- CHU de Nancy - Brabois
-
Contact:
- Pierre Feugier, MD
-
Nantes, France
- Recruiting
- CHU de Nantes - Hotel Dieu
-
Contact:
- Béatrice MAHE, MD
-
Nantes, France
- Recruiting
- Centre Catherine de Sienne
-
Contact:
- Nadine MORINEAU, MD
-
Nice, France
- Recruiting
- Centre Antoine Lacassagne
-
Contact:
- Fréderic PEYRADE, Pr
-
Nice, France
- Recruiting
- CHU de Nice
-
Contact:
- Edmond CHICHE, MD
-
Orleans, France
- Recruiting
- CHR d'Orléans
-
Contact:
- Marlène OCHMANN, MD
-
Paris Cedex 10, France
- Recruiting
- APHP - Hopital Saint Louis
-
Contact:
- Catherine THIEBLEMONT, Pr
-
Pierre-Bénite Cedex, France
- Recruiting
- CHU Lyon Sud
-
Contact:
- Emmanuel BACHY, MD
-
Rennes, France
- Recruiting
- CHU de Rennes - Hopital de Pontchaillou
-
Contact:
- Roch HOUOT, MD
-
Rouen, France
- Recruiting
- Centre Henri Becquerel
-
Contact:
- Fabrice JARDIN, Pr
-
Saint-Priest-en-Jarez, France
- Recruiting
- Institut de Cancérologie de la Loire Lucien Neuwirth
-
Contact:
- Ludovic FOUILLET, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a diagnosis of MZL, of extranodal (EMZL) or splenic (SMZL based on the Matutes score and CD20 + CD11c + CD180 + CD43 + CD200 expression and validated by a centralized review) or nodals (NMZL) subtypes. In case of large dissemination, disseminated MZL will be included as DMZL and included in NMZL subtype.
- Have been treated with at least one prior systemic treatment and not more than three prior lines. Previous line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib (at least 1 month). Patients should not have received Lenalidomide before. Prior local therapy (including surgery, radiotherapy antibiotics for H. pylori-positive gastric lymphoma, and antiviral for hepatitis C virus) is not considered as one line of treatment
- Signed Informed Consent Form
- Age ≥ 18 years at the time of signing the informed consent form
- Ability to comply with the study protocol and procedures and required hospitalizations, in the investigator's judgement
- Eastern Cooperative Oncology Group (ECOG) performance score (PS) of ≤ 2
- Have a symptomatic disease requiring a systemic treatment
- Not eligible for a local treatment including radiotherapy or surgery
- Stage I disease of EMZL, SMZL or NMZL may be eligible only if not candidate to local therapy (surgery or radiotherapy).
Measurable disease in at least two perpendicular dimensions on an imaging scan is defined as: lymph node or nodal mass bi-dimensional measurement with ≥ 15 mm in longest transverse diameter or the short diameter must measure ≥ 10 mm regardless of the longest transverse diameter.
Spleen is considered as a measurable disease if vertical axis is higher than 13 cm.
Adequate hematopoietic function at screening as follows unless cytopenia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune thrombocytopenia:
11.1. Platelet count ≥ 75 G/L; in cases of thrombocytopenia clearly due to marrow involvement of MZL or hypersplenism or auto-immune thrombocytopenia, platelet count should be ≥ 30 G/L Washout platelet transfusion is 7 days between transfusion and D1 of starting treatment 11.2. Absolute Neutrophil Count (ANC ) ≥ 1 G/L unless neutropenia is clearly due to marrow involvement of MZL or hypersplenism. Granulocyte Colony-Stimulating Factor (G-CSF) is not allowed within 7 days before starting treatment 11.3. Total hemoglobin ≥ 8 g/dL unless anemia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune hemolytic anemia. Washout erythrocyte transfusion is 7 days between transfusion and D1 of starting treatment
- Serum total bilirubin ≤ 1.5 x the upper limit of normal (ULN) (or ≤3 x ULN for patients with Gilbert syndrome),
- Aspartate Transaminase (AST) or ALanine Transaminase (ALT) ≤ 2.5 x ULN, unless directly attributable to the patient's MZL
- Measured or estimated creatinine clearance ≥ 40 mL/min by institutional standard method
- Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation. Patients who are hepatitis B surface antigen (HBsAg) negative, hepatitis B surface antibody (anti-HBsAb) positive and hepatitis B core antibody (HBcAb) negative are eligible,
16. Contraception: 16.1. For women of childbearing potential (WOCBP) (refer to section 14.6.1 and 14.6.1.1): Serum test pregnancy at screening and Day 1 before first dose. And then monthly until end of treatment. Efficient contraceptive method is required during the treatment period (including periods of treatment interruption), for at least 28 days after the final dose of Lenalidomide (if applicable), 3 months after the final dose of Mosunetuzumab (if applicable), 6 months after the final dose of chemotherapies (if applicable) and 12 months after the final dose of Rituximab (if applicable).
16.2. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period (including periods of treatment interruption), and for at least 28 days after the final dose of Lenalidomide (if applicable), 3 months after the final dose of Mosunetuzumab and Tocilizumab (if applicable), 6 months after the final dose of chemotherapies (if applicable) and 12 months after the final dose of Rituximab) (if applicable).
- Patient covered by any social security system (France)
Exclusion Criteria:
- MZL with histologic transformation to high-grade lymphoma
- Pregnant or breastfeeding or intending to become pregnant during the study or within 28 days after the final dose of Lenalidomide, 3 months after the final dose of Mosunetuzumab and Tocilizumab (if applicable), 6 months after the final dose of chemotherapies and 12 months after the final dose of Rituximab (if applicable). Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.
Participants who have received any of the following treatments prior to study entry:
- Treatment with Mosunetuzumab or other CD20/CD3-directed bispecific antibodies
- Allogeneic stem cell transplant
Participants who have received any of the following treatments, whether investigational or approved, within the respective time periods prior to initiation of study treatment:
- Radiotherapy within 2 weeks prior to the first dose of study treatment
- Autologous stem cell transplant within 100 days prior to first study treatment
- Use of monoclonal antibodies within 4 weeks prior to first study treatment
- Systemic immunosuppressive medications (including, but not limited to, Cyclophosphamide, Azathioprine, Methotrexate, Thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to first dose of study treatment (C1D1); Systemic corticosteroid treatment <20 mg/day prednisone or equivalent and inhaled corticosteroids are permitted. Last dose of corticosteroid ≥20 mg/day prednisone or equivalent will not be permitted during the last 15 days before inclusion.
Administration of acute, low-dose, systemic immunosuppressant medications (e.g., single dose of 4 mg/day of dexamethasone for nausea or B-symptoms) is permitted during 4 days without washout.
- Any other anti-cancer investigational therapy within 4 weeks prior to initiation of study treatment.
- Received a live, attenuated vaccine within 4 weeks before first dose of study treatment, or in whom it is anticipated that such a live attenuated vaccine will be required during the study period or within 5 months after the final dose of study treatment, except for acute pandemic situation such COVID19
- Active or history of Central Nervous System (CNS) lymphoma or leptomeningeal infiltration
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins) - grade 3 and 4
- Known hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the Mosunetuzumab, Rituximab, Tocilizumab, Lenalidomide, or Thalidomide formulation, including Mannitol
- Patients unable to receive adequate prophylaxis and/or therapy for thromboembolic events (aspirin or low molecular weight heparin)
History of prior malignancy, except for conditions as listed below if patients have recovered from the acute side effects incurred as a result of previous therapy:
- Malignancies treated with curative intent and with no known active disease present for ≥2 years before enrollment
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- Surgically/adequately treated low grade, early stage I, localized prostate in situ carcinoma
- Participants with infections requiring IV treatment with antibiotics or hospitalization (Grade 3 or 4) within the last 4 weeks prior to inclusion or known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds),
Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to:
- Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure | American Heart Association)], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina)
- Significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
- Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
- Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed. Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible.
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Known Positive serologic HIV test at screening
- Acute or chronic hepatitis C virus (HCV) infection Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation.
- Known or suspected history of hemophagocytic lymphohistiocytosis
- Known or suspected chronic active Epstein-Barr virus (EBV) infection within the last 4 weeks prior to inclusion
- History of erythema multiforme, Grade ≥3 rash, or blistering following prior treatment with immunomodulatory derivatives
- History of interstitial lung disease (ILD), drug-induced pneumonitis, and autoimmune pneumonitis
- Active autoimmune disease requiring treatment
History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis; except:
- Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.
- Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
- Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible.
- Patients with a remote history of, or well-controlled autoimmune disease, with a treatment-free interval from immunosuppressive therapy for 12 months may be eligible after review and discussion with the Medical Monitor.
- Recent major surgery with risk of bleeding within 4 weeks prior to first study treatment administration (C1D1)
- History of solid organ transplantation
- Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
- Person deprived of his/her liberty by a judicial or administrative decision
- Person hospitalized without consent
- Adult person under legal protection
- Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
- Patient unable to receive at least one of the three regimens of the comparator arm (ICT). As in usual practice, physician has to verify the absence of contraindication to the use of the drugs, hypersensitivity, and to take into account the lymphoma history and previous treatment scheme used.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: Mosunetuzumab and Lenalidomide
- Mosunetuzumab and Lenalidomide
|
Other Names:
|
Active Comparator: Arm 2: Rituximab-Lenalidomide (28-days cycles)
|
Other Names:
|
Active Comparator: Arm 3: Rituximab-Bendamustine (28-days cycles)
|
Other Names:
|
Active Comparator: Arm 4: Rituximab-CHOP (21-days cycles
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS) as determined by investigator
Time Frame: After 122 events = approximately 4.5 years and after 163 events = approximately 6.5 years (event = progression or death)
|
according to Lugano criteria 2014
|
After 122 events = approximately 4.5 years and after 163 events = approximately 6.5 years (event = progression or death)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response rate (CR) as determined by investigator (CR24)
Time Frame: 2 years
|
according to Lugano criteria 2014
|
2 years
|
Complete response rate (CR) by blinded central review (CR24)
Time Frame: 2 years
|
based on PET result according to Lugano Criteria 2014
|
2 years
|
Overall response rate (ORR) as determined by investigator
Time Frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
according to Lugano Criteria 2014
|
6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
Overall response rate (ORR) as determined by investigator
Time Frame: 12 months
|
according to Lugano Criteria 2014
|
12 months
|
Overall response rate (ORR) as determined by investigator
Time Frame: 24 months
|
according to Lugano Criteria 2014
|
24 months
|
Overall response rate (ORR) as determined by investigator
Time Frame: 36 months
|
according to Lugano Criteria 2014
|
36 months
|
Overall response rate (ORR) as determined by investigator
Time Frame: 48 months
|
according to Lugano Criteria 2014
|
48 months
|
Overall response rate (ORR) as determined by investigator
Time Frame: 60 months
|
according to Lugano Criteria 2014
|
60 months
|
Overall response rate (ORR) by blinded central review
Time Frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
based on PET result according to Lugano Criteria 2014
|
6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
Overall response rate (ORR) by blinded central review
Time Frame: 12 months
|
based on PET result according to Lugano Criteria 2014
|
12 months
|
Overall response rate (ORR) by blinded central review
Time Frame: 24 months
|
based on PET result according to Lugano Criteria 2014
|
24 months
|
Overall response rate (ORR) by blinded central review
Time Frame: 36 months
|
based on PET result according to Lugano Criteria 2014
|
36 months
|
Overall response rate (ORR) by blinded central review
Time Frame: 48 months
|
based on PET result according to Lugano Criteria 2014
|
48 months
|
Overall response rate (ORR) by blinded central review
Time Frame: 60 months
|
based on PET result according to Lugano Criteria 2014
|
60 months
|
CR rate other than CR24 as determined by investigator
Time Frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
according to Lugano Criteria 2014
|
6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
CR rate other than CR24 as determined by investigator
Time Frame: 12 months
|
according to Lugano Criteria 2014
|
12 months
|
CR rate other than CR24 as determined by investigator
Time Frame: 24 months
|
according to Lugano Criteria 2014
|
24 months
|
CR rate other than CR24 as determined by investigator
Time Frame: 36 months
|
according to Lugano Criteria 2014
|
36 months
|
CR rate other than CR24 as determined by investigator
Time Frame: 48 months
|
according to Lugano Criteria 2014
|
48 months
|
CR rate other than CR24 as determined by investigator
Time Frame: 60 months
|
according to Lugano Criteria 2014
|
60 months
|
CR rate other than CR24 by blinded central review
Time Frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
based on PET result according to Lugano Criteria 2014
|
6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
|
CR rate other than CR24 by blinded central review
Time Frame: 12 months
|
based on PET result according to Lugano Criteria 2014
|
12 months
|
CR rate other than CR24 by blinded central review
Time Frame: 24 months
|
based on PET result according to Lugano Criteria 2014
|
24 months
|
CR rate other than CR24 by blinded central review
Time Frame: 36 months
|
based on PET result according to Lugano Criteria 2014
|
36 months
|
CR rate other than CR24 by blinded central review
Time Frame: 48 months
|
based on PET result according to Lugano Criteria 2014
|
48 months
|
CR rate other than CR24 by blinded central review
Time Frame: 60 months
|
based on PET result according to Lugano Criteria 2014
|
60 months
|
Duration of response (DOR)
Time Frame: 6.5 years
|
6.5 years
|
|
Event-free survival (EFS)
Time Frame: 6.5 years
|
6.5 years
|
|
Time to next anti-lymphoma treatment (TTNLT)
Time Frame: 6.5 years
|
6.5 years
|
|
Histological transformation rate
Time Frame: 6.5 years
|
6.5 years
|
|
Safety: incidence and severity of Adverse Events (AE), of Serious Adverse Events (SAE), of Cytokine Release Syndrome (CRS), of AE grade 3 or 4 of study-drug_related events, incidence of Death and Secondary Primary Malignancies
Time Frame: 6.5 years
|
6.5 years
|
|
Tolerability : number of dose interruptions, dose reductions, and dose intensity, and study treatment discontinuation because of adverse events
Time Frame: 6.5 years
|
6.5 years
|
|
Health related quality of life as measured by the EQ-5D-5L
Time Frame: 7 months
|
7 months
|
|
Health related quality of life as measured by the EQ-5D-5L
Time Frame: 12 months
|
12 months
|
|
Health related quality of life as measured by the EQ-5D-5L
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Catherine THIEBLEMONT, Pr, Lymphoma Study Association
- Principal Investigator: Sylvain CARRAS, Lymphoma Study Association
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, B-Cell, Marginal Zone
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Bendamustine Hydrochloride
- Rituximab
Other Study ID Numbers
- MARSUN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Marginal Zone Lymphoma
-
Narendranath EpperlaWithdrawnRecurrent Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Nodal Marginal Zone Lymphoma | Recurrent Nodal Marginal Zone Lymphoma | Recurrent Splenic Marginal Zone Lymphoma | Refractory Splenic Marginal Zone Lymphoma and other conditions
-
International Extranodal Lymphoma Study Group (IELSG)Active, not recruitingSplenic Marginal Zone Lymphoma | Marginal Zone Lymphoma | Nodal Marginal Zone LymphomaFrance, Switzerland, Italy, Belgium, Portugal
-
Narendranath EpperlaNot yet recruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic... and other conditionsUnited States
-
International Extranodal Lymphoma Study Group (IELSG)CompletedMarginal Zone B-cell LymphomaItaly, France
-
National Cancer Institute (NCI)WithdrawnExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone LymphomaUnited States
-
International Extranodal Lymphoma Study Group (IELSG)Not yet recruitingSplenic Marginal Zone LymphomaNorway, Denmark, Sweden, Italy, Switzerland
-
University of MiamiADC Therapeutics S.A.RecruitingMarginal Zone LymphomaUnited States
-
International Extranodal Lymphoma Study Group (IELSG)RecruitingMarginal Zone LymphomaFrance, Italy, Switzerland
-
University of UlmMerck Sharp & Dohme LLC; Zentrum für Klinische Studien Ulm; X-act Cologne Clinical... and other collaboratorsRecruitingMarginal Zone LymphomaAustria, Germany
Clinical Trials on Mosunetuzumab + Lenalidomide
-
Hoffmann-La RocheActive, not recruitingFollicular LymphomaUnited Kingdom, United States, China, France, Spain
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Follicular LymphomaUnited States
-
Genentech, Inc.RecruitingNon-Hodgkin LymphomaUnited States, Puerto Rico
-
Hoffmann-La RocheRecruitingSystemic Lupus ErythematosusUnited States, Poland, Ukraine, Georgia, Moldova, Republic of
-
M.D. Anderson Cancer CenterGenentech, Inc.WithdrawnRefractory B-cell Acute Lymphoblastic LeukemiaUnited States
-
Brown UniversityGenentech, Inc.RecruitingFollicular Lymphoma | B-cell Lymphoma | Marginal Zone LymphomaUnited States
-
Weill Medical College of Cornell UniversityEpizyme, Inc.; Genentech, Inc.Recruiting
-
Washington University School of MedicineGenentech, Inc.RecruitingDiffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed B-Cell Lymphoma | Follicular Lymphoma Grade 3BUnited States
-
Washington University School of MedicineGenentech, Inc.RecruitingB Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | Aggressive Lymphoma | Follicular Lymphoma Grade 3United States
-
Hoffmann-La RocheRecruitingRelapsed or Refractory Follicular LymphomaUnited States, Korea, Republic of, Taiwan, China, Spain, United Kingdom, Australia, France, Germany, Japan, Turkey, Brazil, Poland, Ukraine, Italy, Russian Federation